The stock price’s performance over the year has been unpredictable, resulting in a mix of pessimistic and optimistic outlooks among investors. Year to date metric has recorded a loss of -13.92%.However, over the last six months, we can see a stronger performance of -9.93%. Over the last 30 days, the price of INM has fallen by 32.04%. And in the last five days, it has surged by 47.83%.
InMed Pharmaceuticals Inc’s market performance has been unstable in recent times.
52-week price history of INM Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. InMed Pharmaceuticals Inc’s current trading price is -74.01% away from its 52-week high, while its distance from the 52-week low is 137.21%. The stock’s price range during this period has varied between$1.72 and $15.70. The InMed Pharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 69.16 million for the day, a figure considerably higher than their average daily volume of 93980.0 over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
InMed Pharmaceuticals Inc (INM) has experienced a quarterly rise of 43.16% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 4.93M and boasts a workforce of 13 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
INM’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for INM stands at 0.12. Similarly, the long-term debt-to-equity ratio is also 0.06.
